A Two Part Trial Investigating the Safety of NN9924 in Healthy Male Subjects

Subjects will be randomized to receive a single dose of NN9924, at escalating dose levels. Progression to next dose will be based on safety evaluation.

Subjects will receive a single dose of placebo as a comparator to NN9924, at all dose levels.

Subjects will be randomized to receive a single dose of NN9924 in one of three different concentrations. The dose will be selected based on the results of part 1.

Subjects will be randomized to receive a single dose of placebo.

As an active comparator, one standard dose will be given s.c. (under the skin) at one study visit

As an active comparator, one standard dose will be given i.v. (into the vein) at one study visit.